These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 38516396)

  • 1. Integrating virtual screening, pharmacoinformatics profiling, and molecular dynamics: identification of promising inhibitors targeting 3CLpro of SARS-CoV-2.
    Mohammad A; Zheoat A; Oraibi A; Manaithiya A; S Almaary K; Allah Nafidi H; Bourhia M; Kilani-Jaziri S; A Bin Jardan Y
    Front Mol Biosci; 2023; 10():1306179. PubMed ID: 38516396
    [No Abstract]   [Full Text] [Related]  

  • 2. Discovery of putative inhibitors against main drivers of SARS-CoV-2 infection: Insight from quantum mechanical evaluation and molecular modeling.
    Balogun TA; Chukwudozie OS; Ogbodo UC; Junaid IO; Sunday OA; Ige OM; Aborode AT; Akintayo AD; Oluwarotimi EA; Oluwafemi IO; Saibu OA; Chuckwuemaka P; Omoboyowa DA; Alausa AO; Atasie NH; Ilesanmi A; Dairo G; Tiamiyu ZA; Batiha GE; Alkhuriji AF; Al-Megrin WAI; De Waard M; Sabatier JM
    Front Chem; 2022; 10():964446. PubMed ID: 36304744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening marine algae metabolites as high-affinity inhibitors of SARS-CoV-2 main protease (3CLpro): an in silico analysis to identify novel drug candidates to combat COVID-19 pandemic.
    Muteeb G; Alshoaibi A; Aatif M; Rehman MT; Qayyum MZ
    Appl Biol Chem; 2020; 63(1):79. PubMed ID: 33251389
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Potential Inhibitors of 3CL Protease of SARS-CoV-2 From ZINC Database by Molecular Docking-Based Virtual Screening.
    Abdusalam AAA; Murugaiyah V
    Front Mol Biosci; 2020; 7():603037. PubMed ID: 33392261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. QSAR modeling and pharmacoinformatics of SARS coronavirus 3C-like protease inhibitors.
    Ishola AA; Adedirin O; Joshi T; Chandra S
    Comput Biol Med; 2021 Jul; 134():104483. PubMed ID: 34020129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral evaluation of hydroxyethylamine analogs: Inhibitors of SARS-CoV-2 main protease (3CLpro), a virtual screening and simulation approach.
    Gupta Y; Kumar S; Zak SE; Jones KA; Upadhyay C; Sharma N; Azizi SA; Kathayat RS; Poonam ; Herbert AS; Durvasula R; Dickinson BC; Dye JM; Rathi B; Kempaiah P
    Bioorg Med Chem; 2021 Oct; 47():116393. PubMed ID: 34509862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multidimensional virtual screening approaches combined with drug repurposing to identify potential covalent inhibitors of SARS-CoV-2 3CL protease.
    Wang Y; Gao Q; Yao P; Yao Q; Zhang J
    J Biomol Struct Dyn; 2023; 41(24):15262-15285. PubMed ID: 36961210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chetomin, a SARS-CoV-2 3C-like Protease (3CL
    Ibrahim MAA; Abdelrahman AHM; Mohamed DEM; Abdeljawaad KAA; Naeem MA; Gabr GA; Shawky AM; Soliman MES; Sidhom PA; Paré PW; Hegazy MF
    Viruses; 2023 Jan; 15(1):. PubMed ID: 36680290
    [TBL] [Abstract][Full Text] [Related]  

  • 10. QSAR based virtual screening derived identification of a novel hit as a SARS CoV-229E 3CL
    Jawarkar RD; Bakal RL; Zaki MEA; Al-Hussain S; Ghosh A; Gandhi A; Mukerjee N; Samad A; Masand VH; Lewaa I
    Arab J Chem; 2022 Jan; 15(1):103499. PubMed ID: 34909066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of apigenin-based biflavonoid derivatives as potential therapeutic agents against viral protease (3CLpro) of SARS-CoV-2 via molecular docking, molecular dynamics and quantum mechanics studies.
    Abdizadeh R; Hadizadeh F; Abdizadeh T
    J Biomol Struct Dyn; 2023; 41(13):5915-5945. PubMed ID: 35848354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of potential antivirals against 3CLpro enzyme for the treatment of SARS-CoV-2: A multi-step virtual screening study.
    Kumar V; Kar S; De P; Roy K; Leszczynski J
    SAR QSAR Environ Res; 2022 May; 33(5):357-386. PubMed ID: 35380087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of repurposing therapeutics toward SARS-CoV-2 main protease by virtual screening.
    Sanachai K; Somboon T; Wilasluck P; Deetanya P; Wolschann P; Langer T; Lee VS; Wangkanont K; Rungrotmongkol T; Hannongbua S
    PLoS One; 2022; 17(6):e0269563. PubMed ID: 35771802
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Prabhakaran P; Hebbani AV; Menon SV; Paital B; Murmu S; Kumar S; Singh MK; Sahoo DK; Desai PPD
    Front Microbiol; 2023; 14():1194794. PubMed ID: 37448573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virtual screening and molecular simulation study of natural products database for lead identification of novel coronavirus main protease inhibitors.
    Tripathi N; Goel B; Bhardwaj N; Sahu B; Kumar H; Jain SK
    J Biomol Struct Dyn; 2022 May; 40(8):3655-3667. PubMed ID: 33213294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting SARS-CoV-2 main protease: structure based virtual screening, in silico ADMET studies and molecular dynamics simulation for identification of potential inhibitors.
    Uniyal A; Mahapatra MK; Tiwari V; Sandhir R; Kumar R
    J Biomol Struct Dyn; 2022 May; 40(8):3609-3625. PubMed ID: 33226303
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Black tea bioactives as inhibitors of multiple targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): a virtual screening and molecular dynamic simulation study.
    Gogoi M; Borkotoky M; Borchetia S; Chowdhury P; Mahanta S; Barooah AK
    J Biomol Struct Dyn; 2022 Sep; 40(15):7143-7166. PubMed ID: 33715595
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Finding potent inhibitors against SARS-CoV-2 main protease through virtual screening, ADMET, and molecular dynamics simulation studies.
    Roy R; Sk MF; Jonniya NA; Poddar S; Kar P
    J Biomol Struct Dyn; 2022 Sep; 40(14):6556-6568. PubMed ID: 33682642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Virtual screening and molecular dynamics simulation analysis of Forsythoside A as a plant-derived inhibitor of SARS-CoV-2 3CLpro.
    Bibi S; Khan MS; El-Kafrawy SA; Alandijany TA; El-Daly MM; Yousafi Q; Fatima D; Faizo AA; Bajrai LH; Azhar EI
    Saudi Pharm J; 2022 Jul; 30(7):979-1002. PubMed ID: 35637849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacophore Model for SARS-CoV-2 3CLpro Small-Molecule Inhibitors and
    Glaab E; Manoharan GB; Abankwa D
    J Chem Inf Model; 2021 Aug; 61(8):4082-4096. PubMed ID: 34348021
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.